Showing 3581-3590 of 5154 results for "".
- Curology Survey: Back-to-School Skin Woes Plague Studentshttps://practicaldermatology.com/news/curology-survey-back-to-school-skin-woes-plague-students/2461903/When thinking of going back to school, nearly 72% of students report feeling the pressure to look "perfect" by higher beauty standards set by social media, according to a survey of 2,000 American teens and young adults sponsored by Curology. What’s more, 25% of students
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and accept
- US FDA Grants Breakthrough Device Designation to Marpe's Dermatology Screening Systemhttps://practicaldermatology.com/news/us-fda-grants-breakthrough-device-designation-to-marpes-dermatology-screening-system/2461900/The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Marpe Technologies full-body Dermatology Screening System. The Marpe System is designed to acquire and analyze total body images to support the identification of malignant and pre-malignant lesions,
- A Clinician's Guide to Alopecia: Diagnosis, Treatment, and Preventionhttps://practicaldermatology.com/news/a-clinicians-guide-to-alopecia-diagnosis-treatment-and-prevention/2461898/Hair loss, also known as alopecia, is a prevalent condition that affects people across every demographic.1 Unlike other skin issues that may remain unnoticed for extended periods, hair loss is often immediately apparent to the patient. Recently, alopecia has gained significant media at
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- Research Validates Atopic March Patternhttps://practicaldermatology.com/news/research-validates-the-atopic-march/2461889/New research validates a population-level pattern of the “allergic march” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The average peak age of onset was approximately four months for eczema, 13 months
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets,
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde